MedTrace Logo

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

NCT02620800 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-10-22

No results posted yet for this study

Summary

The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic pancreatic adenocarcinoma.

Conditions

  • Metastatic Pancreas Adenocarcinoma

Interventions

DRUG

5FU

5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump

DRUG

nab-paclitaxel

nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15

DRUG

bevacizumab

bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15

DRUG

calcium leucovorin

calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15

DRUG

oxaliplatin

oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Chrystal Louis, MD · Celgene

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-18
Primary Completion
2018-10-29
Completion
2018-10-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02620800 on ClinicalTrials.gov